Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07416552 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Not yet
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07416552 is a Phase 1 study that has not yet begun recruiting, run by Hoffmann-La Roche. The registered enrollment target is 180 participants.
The verdict
NCT07416552, a Phase 1 study, has not yet begun recruiting, sponsored by Hoffmann-La Roche.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.
Interventions
- DRUG SPLIT Abs
- DRUG 203Pb-DOTAM
- DRUG 212Pb-DOTAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2034-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07416552
The ClinicalTrials.gov registry entry for NCT07416552 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SPLIT Abs is the first listed.
NCT07416552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07416552 about?
NCT07416552 is a clinical study titled "A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)". This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therap...
What is the current status of trial NCT07416552?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-07-31. Estimated completion is 2034-02-12.
What interventions are being tested in trial NCT07416552?
The interventions under investigation include: SPLIT Abs (DRUG), 203Pb-DOTAM (DRUG), 212Pb-DOTAM (DRUG).
Who is sponsoring clinical trial NCT07416552?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.